ERBB2 and breast cancer: Regarding neoadjuvant chemotherapy, several studies in the last years have compared anthracycline-containing versus anthracycline-free regimens in HER2-positive BC, showing non-inferiority of anthracycline free-treatment schedules in terms of pCR rates and survival.